Beyond The Numbers: 6 Analysts Discuss Illumina Stock

Loading...
Loading...

In the last three months, 6 analysts have published ratings on Illumina ILMN, offering a diverse range of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 0 4 1 1 0
Last 30D 0 0 1 0 0
1M Ago 0 2 0 1 0
2M Ago 0 0 0 0 0
3M Ago 0 2 0 0 0

Analysts have recently evaluated Illumina and provided 12-month price targets. The average target is $179.83, accompanied by a high estimate of $258.00 and a low estimate of $100.00. Witnessing a positive shift, the current average has risen by 71.27% from the previous average price target of $105.00.

Investigating Analyst Ratings: An Elaborate Study

The standing of Illumina among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Catherine Ramsey Baird Raises Neutral $128.00 $125.00
Luke Sergott Barclays Raises Underweight $100.00 $85.00
Mason Carrico Stephens & Co. Maintains Overweight $170.00 -
Conor McNamara RBC Capital Maintains Outperform $253.00 -
Mason Carrico Stephens & Co. Maintains Overweight $170.00 -
Conor McNamara RBC Capital Maintains Outperform $258.00 -

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Illumina. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Illumina compared to the broader market.
  • Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Illumina's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Illumina analyst ratings.

Unveiling the Story Behind Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Financial Milestones: Illumina's Journey

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Illumina's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 3.6%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -15.6%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Illumina's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.01%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.73%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.39, Illumina adopts a prudent financial strategy, indicating a balanced approach to debt management.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...